Block Admission and Total Voting Rights

RNS Number : 3995A

ReNeuron Group plc

28 September 2015

 

28 September 2015

AIM: RENE

ReNeuron Group plc

("ReNeuron" or "the Company")

Block Admission and Total Voting Rights

Guildford, UK, 28 September 2015: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, today announces that an application has been made to the London Stock Exchange plc for a block admission of 97,015,627 ordinary shares of 1p each in the capital of the Company ("New Ordinary Shares") to be admitted to trading on AIM ("Block Admission"). 

These New Ordinary Shares shall be issued and allotted from time to time pursuant to the exercise of options under the Company's share option schemes. The New Ordinary Shares, when issued, shall rank equally with the Company's existing issued ordinary shares.

The Company currently has 1,145,786 of unallotted shares under its existing 'Share-based payment agreements' block listing scheme which was originally admitted to AIM on 13 May 2010. During the period 13 September 2014 to 28 September 2015, 500,000 shares were issued and allotted pursuant to option exercises which reduced the previous balance of 1,645,786 unallotted shares to 1,145,786 unallotted shares. Following the Block Admission of 97,015,627 New Ordinary Shares, there will be 98,161,413 unallotted shares under the schemes.

Total Voting Rights

Following the issue and allotment of 500,000 shares pursuant to the exercise of options referred to above, the Company has 3,156,739,639 ordinary shares in issue, all with voting rights. The Company holds no ordinary shares in treasury.  The figure of 3,156,739,639 Ordinary Shares may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Enquiries:

ReNeuron	[phone]
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan	[phone]
Mark Court, Sophie Cowles, Stephanie Watson
Cenkos Securities	[phone]
Stephen Keys, Dr Christopher Golden (NOMAD and Broker)
Russell Kerr (Sales)

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development business.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company's therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for the blindness-causing disease, retinitis pigmentosa, is about to enter the clinic in the US.    

ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting a range of cancers.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.

 

END

 

 

MSCMMGZLMRNGKZM